Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Press Releases
Soligenix, Inc.  
December 16, 2024

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

FLASH2 Study opens patient enrollment

avatar profile Olean Times Herald

Olean Times Herald


Local & Social